Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipeline
The company said it has FDA alignment on a registrational path for AATD drug WVE-006 and reported $431.0 million in cash as of September 30, 2026.
Wave Life Sciences reported financial results for the quarter ended September 30, 2026 on October 27, 2026. In October 2026, the company announced alignment with the FDA on key aspects of its planned registrational pathway for WVE-006, with planning underway for a two-year registrational trial to support potential full approval and a one-year interim analysis that could support accelerated approval based on AATD biomarkers.1 The FDA also supports Wave's use of its LC-MS assay to measure wild-type M-AAT and mutant Z-AAT protein for the WVE-006 registrational program.1 The company said it plans to share data from the 600 mg monthly multidose cohort of the WVE-006 trial in the fourth quarter of 2026.1
For WVE-007 in obesity, dosing is underway in the Phase 2a portion of the INLIGHT trial among people with higher BMI, 35 to 50 kg/m2, with and without type 2 diabetes, enrolling in the U.S. and Europe.1 A placebo-controlled Phase 2a combination study is testing 240 mg and 400 mg doses of WVE-007 alongside weekly tirzepatide, compared with tirzepatide alone, in people with obesity and type 2 diabetes.1 The company said it expects data from the Phase 1 600 mg single-ascending-dose cohort in the fourth quarter of 2026, and remains on track to start a maintenance trial testing WVE-007 after stopping incretin therapy in the same quarter.1
A clinical trial application for WVE-008, targeting PNPLA3 I148M liver disease, remains on track for filing in the fourth quarter of 2026.1
On the corporate side, Wave said GSK selected a hepatology development candidate in September 2026 using Wave's proprietary siRNA with SpiNA design, triggering a $12 million milestone payment to Wave.1 Three more collaboration programs are advancing toward candidate selection, with Wave eligible for $330 million to $375 million in milestones per program plus tiered royalties on sales.1
Cash, cash equivalents, and marketable securities totaled $431.0 million as of September 30, 2026, not including the pending GSK milestone, with runway expected into the third quarter of 2028.1 Net loss for the quarter was $61.9 million, compared with $53.9 million in the prior-year period.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.